Federico Pulido

Federico Pulido i

Universidad Complutense de Madrid - Madrid / Spain
Others
AD Scientific Index ID: 1226331
Complutense University of Madrid
person_outline Federico Pulido's MOST POPULAR ARTICLES
1-) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyF Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti, C Orkin, M Bloch, ...The Lancet 381 (9868), 735-743, 20135842013
2-) Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART studyStrategies for Management of Antiretroviral Therapy (SMART) Study GroupThe Journal of infectious diseases 197 (8), 1133-1144, 20085562008
3-) Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 …P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...The Lancet 393 (10167), 143-155, 20192952019
4-) Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV …Strategies for Management of Antiretroviral Therapy (SMART) Study GroupThe Journal of infectious diseases 197 (8), 1145-1155, 20082602008
5-) The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mlJR Arribas, A Horban, J Gerstoft, G Fätkenheuer, M Nelson, N Clumeck, ...Aids 24 (2), 223-230, 20102312010